FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans

June 2, 2025 2025 ASCO ANALYST AND

INVESTOR EVENT Our goal is to develop transformative therapies to extend and improve the lives of patients with cancer Exhibit 99.1

FORWARD-LOOKING STATEMENTS This

presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, KO-2806 and

tipifarnib, expectations regarding the relative benefits of our product candidates versus competitive therapies, expectations regarding the therapeutic and commercial potential of our product candidates, and expectations regarding our collaboration

with Kyowa Kirin. The words "believe," "may," "should," "will," "estimate," "promise," "plan", "continue," "anticipate,"

"intend," "expect," "potential" and similar expressions (including the negative thereof) are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual

results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: our preclinical studies and clinical trials may not be

successful; the U.S. Food and Drug Administration (FDA) may not agree with our interpretation of the data from clinical trials of our product candidates; we may decide, or the FDA may require us, to conduct additional clinical trials or to modify

our ongoing clinical trials; we may experience delays in the commencement, enrollment, completion or analysis of clinical testing for our product candidates, or in the reporting of data from such clinical testing, or significant issues

regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise, which could result in increased costs and delays, or limit our ability to obtain regulatory approval; our product candidates may not receive

regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of our product candidates could delay or prevent regulatory approval or commercialization; we may not be able to obtain

additional financing; and our collaboration with Kyowa Kirin may not be successful. Additional risks and uncertainties may emerge from time to time, and it is not possible for Kura's management to predict all risk factors and

uncertainties. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Other risks and uncertainties affecting us are described more fully in our filings with the Securities and Exchange

Commission. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. This presentation may also contain statistical, preclinical and clinical data obtained

from and prepared by third parties. The recipient is cautioned not to give undue weight to such disclosures. Neither the Company nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any

obligation to update such data after the date of this presentation.

ACUTE MYELOID LEUKEMIA (AML)

Approximately 22,010 people are diagnosed with AML each year in the United States1 5-year survival rate for AML is 33% and as low as 8.6% for patients aged 65 years2 Significant unmet need remains for AML patients Up to 50% of AML patients

may benefit from menin inhibitor therapy2-7 American Cancer Society. Accessed May 25, 2025. https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html National Cancer Institute. Accessed May 25, 2025.

https://seer.cancer.gov/statfacts/html/amyl.html Issa GC et al. Leukemia. 2021;35(9):2482-2495. doi:10.1038/s41375- 021-01309-y Candoni A, Coppola G. Hematol Rep. 2024;16(2):244-254. doi:10.3390/hematolrep16020024 Bertrums EJM et al. Haematologica.

2023;108(8):2044-2058. doi:10.3324/haematol.2022.281653 National Cancer Institute. Accessed October 16, 2024. https://seer.cancer.gov/seertools/hemelymph/ 51f6cf59e3e27c3994bd547d/ National Cancer Institute. Accessed October 16, 2024.

ZIFTOMENIB Targeted investigational

menin inhibitor for relapsed/refractory and newly-diagnosed AML New Drug Application (NDA) based on positive results from the Phase 2 KOMET-001 trial NDA granted Priority Review and assigned Prescription Drug User Fee Act (PDUFA) target action date

of November 30, 2025 Kyowa Kirin partnership funds expansive AML development program through 1L U.S. commercialization

AGENDA Ziftomenib Global Development

Plan Ziftomenib in R/R NPM1-m AML: Phase 1b/2 Clinical Activity and Safety Results from the Pivotal KOMET-001 Study Ziftomenib Market Opportunity in R/R NPM1-m AML

KEY OPINION LEADERS AND INVITED

PARTICIPANTS Eunice Wang, M.D. Chief of Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY Professor of Oncology in the Department of Medicine at Roswell Park Amer Zeidan, MBBS Chief, Division of Hematologic Malignancies,

Director of Hematology Early Therapeutics Research, Yale Cancer Center Professor of Medicine (Hematology), Yale University

Ziftomenib in Relapsed / Refractory

(R/R) NPM1-mutant Acute Myeloid Leukemia (AML): Phase 1b/2 Clinical Activity and Safety Results from the Pivotal KOMET-001 Study Eunice S. Wang1, Pau Montesinos2, Ghayas C. Issa3, James Foran4, Harry Erba5, Eduardo Rodr guez-Arbol 6,

Kateryna Fedorov7, Ma l Heiblig8, Florian Heidel9, Jessica K. Altman10, Maria R. Baer11, Lionel Ades12, Kristen Pettit13, Pierre Peterlin14, Cristina Papayannidis15, Zijing Zhang16, Marcie Riches16, Daniel Corum16, Mollie Leoni16, and Amir T.

Fathi17 1Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; 2Hospital Universitari i Polit cnic La Fe, Valencia, Spain; 3The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4Mayo Clinic Comprehensive Cancer Center,

Mayo Clinic, Jacksonville, FL, USA; 5Duke Cancer Institute, Durham, NC, USA; 6Hospital Universitario Virgen del Roc o, Instituto de Biomedicina de Sevilla (IBiS/CSIC), University of Seville, Seville, Spain; 7Vanderbilt-Ingram Cancer Center,

Nashville, TN, USA; 8Centre Hospitalier Lyon Sud, Lyon, France; 9Hannover Medical School, Hannover, Germany; 10Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA; 11University of Maryland Greenebaum Comprehensive

Cancer Center, Baltimore, MD, USA; 12H pital Saint-Louis, Paris, France; 13University of Michigan, Ann Arbor, MI, USA; 14CHU de Nantes-H tel-Dieu, Nantes, France; 15IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia

"Ser gnoli", Bologna, Italy; 16Kura Oncology, Inc., San Diego, CA, USA; 17Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Eunice S. Wang, M.D., Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

KOMET-001: PIVOTAL TRIAL OF ZIFTOMENIB

MONOTHERAPY IN R/R NPM1-m AML Phase 1a Dose Escalation Phase 1b Validation Cohorts Phase 1b Expansion 50 mg QD ~ ~ 100 mg QD 1000 mg QD Cohort 1: 200 mg QD Cohort 2: 600 mg QD Safety and tolerability Pharmacokinetics Early

evidence of antitumor activity Safety and tolerability Pharmacokinetics Clinical activity Continue enrollment of Phase 1b validation cohort(s) consistent with FDA's Project Optimus Safety and tolerability

Pharmacokinetics Clinical activity Completed Expansion of 600 mg QD Phase 2 Registration-Enabling Primary endpoint: CR/CRh Key secondary endpoints: Duration of CR/CRh CR/CRh MRD negativity Transfusion independence

Adverse events NDA Submitted - Q1 2025 Completed 600 mg QD OBJECTIVES NPM1-m, KMT2A-r, Other NPM1-m or KMT2A-r NPM1-m NPM1-m Completed CR/CRh, complete remission with full or partial hematologic recovery; KMT2A-r, KMT2A-rearranged; MRD,

measurable residual disease; NPM1-m, NPM1-mutated; QD, once daily.

BASELINE CHARACTERISTICS: R/R NPM1-m

AML Data cutoff: Dec 20, 2024. ECOG PS, Eastern Cooperative Oncology Group performance status; HSCT, hematopoietic stem cell transplantation; ITD, internal tandem duplication; QD, once daily; RP2D, recommended phase 2 dose; TKD, tyrosine kinase

domain. n (%) Ziftomenib RP2D 600 mg QD Phase 2 (N=92) Pooled Phase 1b/2 (N=112) Median age, yrs (range) 69 (33-84) 69 (22-86) 18-64 yrs 33 (36) 42 (38) 65 yrs 59 (64) 70 (63) Female 49 (53) 63 (56) Race White 75 (82) 88

(79) Non-White 17 (18) 24 (21) Region United States/Canada 45 (49) 57 (51) Europe 47 (51) 55 (49) ECOG PS 0 27 (29) 30 (27) 1 49 (53) 63 (56) 2 16 (17) 19 (17) Bone marrow aspirate blasts %, median (range) 39.5 (0.5-98) 44.0 (0.5-98) n

(%) Ziftomenib RP2D 600 mg QD Phase 2 (N=92) Pooled Phase 1b/2 (N=112) Co-mutations, n/Na FLT3-ITD 38/84 (45) 43/102 (42) FLT3-TKD 9/84 (11) 11/102 (11) IDH1-m 10/80 (13) 13/97 (13) IDH2-m 16/18 (20) 22/96 (23) Median prior

therapies (range) 2 (1-7) 2 (1-7) 1 32 (35) 37 (33) 2 30 (33) 37 (33) 3 30 (33) 38 (34) Prior HSCT 22 (24) 26 (23) Prior venetoclax 54 (59) 67 (60) Prior menin inhibitor 1 (1) 1 (1) Baseline characteristics were similar between

the phase 2 and pooled phase 1b/2 populations aAmong patients with available co-mutation data at baseline.

RESPONSE & DURATION OF

RESPONSE: R/R NPM1-m AML Primary Phase 2 endpoint met (P-value=0.0058)* vs. 12% historical control rate1 For Phase 2 patients, after a median follow-up of 4.1 months (range, 0.1-19.7): n (%) Ziftomenib RP2D 600 mg QD Phase 2 (N=92) Pooled

Phase 1b/2 (N=112) CR/CRh 21 (23) 28 (25) Overall Response CR CRh CRi/CRp MLFS PR Othera 30 (33) 13 (14) 8 (9) 3 (3) 5 (5) 1 (1) 62 (67) 39 (35) 20 (18) 8 (7) 4 (4) 6 (5) 1 (1) 73 (65) Median Duration of Response, months (95% CI) CR/CRh CRc ORR 3.7

(1.9-NE) 4.6 (2.8-11.4) 4.6 (2.8-11.4) 3.7 (1.9-7.7) 5.1 (2.8-8.1) 4.6 (3.6-7.7) Restricted Mean Duration of Responseb, months (95% CI) CR/CRh CRc ORR 4.3 (3.1-5.6) 5.9 (4.0-7.7) 5.9

(4.4-7.5) 5.2 (3.6-6.7) 6.4 (4.6-8.1) 6.5 (4.9-8.1) MRD negativity, n/Nc (%) 12/19 (63) 17/26 (65) Median time to CR/CRh: 2.8 months (range, 1.0 - 15.0) Median time to ORR: 1.9 months (range, 0.8

- 3.7) Data cutoff: Dec 20, 2024. 1. Smith CC et al. Blood Adv. 2022;6(7):2144-55. CR, complete remission; CRc, composite complete remission; CRh, complete remission with partial hematologic recovery; CRi, CR with incomplete hematologic

recovery; CRp, CR with incomplete platelet recovery; MLFS, morphologic leukemia free state; MRD, measurable residual disease; ORR, overall response rate; PR, partial response; QD, once daily; RP2D, recommended phase 2 dose. aStable disease/no

response/clinical benefit/progressive disease/not evaluable. bDefined as the expected duration of response (area under the Kaplan-Meier curve, up to the time point when 10% of patients remain at risk). cAmong CR/CRh responders evaluated for

MRD (centrally tested). *Based on primary analysis data cut (Oct 28, 2024).

COMPARABLE CR/CRh ACROSS

PRE-SPECIFIED SUBGROUPS: R/R NPM1-m AML Data cutoff: Dec 20, 2024. CR, complete response; CRh, complete response with partial hematologic recovery; ECOG PS, Eastern Cooperative Oncology Group performance status; HSCT, hematopoietic stem cell

transplant; ITD, internal tandem duplication; TKD, tyrosine kinase domain. Comparable CR/CRh rates across pre-specified subgroups, regardless of prior HSCT, venetoclax, or FLT3/IDH co-mutations

a TRANSFUSION INDEPENDENCE: R/R

NPM1-m AML Additional benefit beyond CR/CRh Ziftomenib RP2D 600 mg QD Phase 2 (N=92) Total post-baseline transfusion independence Transfusion conversion (TD to TI) ratea, n/N (%) 17/82 (21) 95% CIb 13-31 Maintenance of transfusion independence

(TI to TI) ratec, n/N (%) 2/10 (20) 95% CIb 3-56 Post-baseline transfusion of red blood cells Transfusion conversion (TD to TI) ratea, n/N (%) 18/75 (24) 95% CIb 15-35 Maintenance of transfusion independence (TI to TI) ratec, n/N

(%) 2/17 (12) 95% CIb 2-36 Post-baseline transfusion of platelets Transfusion conversion (TD to TI) ratea, n/N (%) 12/71 (17) 95% CIb 9-28 Maintenance of transfusion independence (TI to TI) ratec, n/N (%) 8/21 (38) 95% CIb

18-62 aTransfusion conversion rate was defined as the number of patients who were TD at baseline but became TI post-baseline (ie, n) divided by the total number of patients who were TD at baseline. bCI was calculated using the exact method

based on binomial distribution. CTransfusion maintenance rate was defined as the number of patients who were TI at baseline and remained TI post-baseline (ie, n) divided by the total number of patients who were TI at baseline. Post-baseline

transfusion period was defined as the 29 days post-first dose of ziftomenib until last dose prior to any new anti-cancer treatment (HSCT). Data cutoff: Dec 20, 2024. HSCT, hematopoietic stem cell transplantation; QD, once daily; RP2D, recommended

phase 2 dose; TD, transfusion dependent; TI, transfusion independent.

OVERALL SURVIVAL: R/R NPM1-m AML

All Patients (Pooled Phase 1b/2) Responders* vs. Non-Responders *Responders included CRc, MLFS, and PR. Data cutoff: Dec 20, 2024. CRc, composite complete remission; MLFS, morphologic leukemia free state; OS, overall survival; PR, partial response.

Median OS: 6.1 months (95% CI, 3.8-8.4) Note: 24 patients remain alive on-study, with 9 patients on-treatment

SAFETY & TOLERABILITY OF

ZIFTOMENIB IN R/R NPM1-m AML (SAFETY POPULATION) Data cutoff: Dec 20, 2024. 1. Wang ES et al. Lancet Oncol 2024; 25(10):1310-24. 2. Fathi AT et al. Blood. 2024;144(Suppl_1):2880. AE, adverse event; QD, once daily; QTc, corrected QT interval; RP2D,

recommended phase 2 dose. Ziftomenib was well tolerated, with a safety profile consistent with previous studies,1,2 including: Low rates of ziftomenib-related myelosuppression No clinically significant QTc prolongation: 3 (3%)* patients: 1 Gr2, 2

Gr3 (all investigator-assessed) Differentiation syndrome: 15 (13%) Gr3; no Gr4-5 events Treatment-Emergent AEs in 20% of All Patients Event, n (%) Ziftomenib RP2D 600 mg QD Phase 2 (N=92) Pooled Phase 1b/2 (N=112) Any Grade Grade

3 Any Grade Grade 3 Any AE 92 (100) 86 (93) 112 (100) 105 (94) Hematologic AEs Anemia 20 (22) 18 (20) 25 (22) 23 (21) Febrile neutropenia 24 (26) 24 (26) 25 (22) 25 (22) Thrombocytopenia 18 (20) 18 (20) 22 (20) 22 (20) Nonhematologic

AEs Diarrhea 27 (29) 1 (1) 36 (32) 5 (4) Nausea 23 (25) 1 (1) 31 (28) 1 (1) Hypokalemia 22 (24) 12 (13) 29 (26) 13 (12) Differentiation syndrome 23 (25) 14 (15)a 27 (24) 15 (13)a Pruritus 21 (23) 0 26 (23) 0 Peripheral edema 23 (25) 0 25 (22) 0

Pneumonia 19 (21) 13 (14) 24 (21) 17 (15) aNo patients had Grade 4-5 differentiation syndrome. *All 3 patients were on additional medications associated with QTc prolongation: 2 patients had electrolyte abnormalities and 1 patient had prior

diagnosis of atrial fibrillation.

SAFETY & TOLERABILITY OF

ZIFTOMENIB IN R/R NPM1-m AML (SAFETY POPULATION) Data cutoff: Dec 20, 2024. 1. Wang ES et al. Lancet Oncol. 2024; 25(10):1310-24. 2. Fathi AT et al. Blood. 2024;144(Suppl_1):2880. AE, adverse event; QD, once daily; QTc, corrected QT interval; RP2D,

recommended phase 2 dose. Ziftomenib-related AEs in 5% of All Patients Event, n (%) Ziftomenib RP2D 600 mg QD Phase 2 (N=92) Pooled Phase 1b/2 (N=112) Any Grade Grade 3 Any Grade Grade 3 Any ziftomenib-related AE 64 (70) 37 (40)

77 (69) 45 (40) Hematologic AEs Anemia 5 (5) 5 (5) 6 (5) 6 (5) Neutropenia 6 (7) 6 (7) 6 (5) 6 (5) Nonhematologic AEs Differentiation syndrome 22 (24) 14 (15)a 26 (23) 15 (13)a Pruritus 15 (16)

0 16 (14) 0 Nausea 8 (9) 0 13 (12) 0 Diarrhea 8 (9) 0 10 (9) 2 (2) Alanine aminotransferase increased 6 (7) 2 (2) 7 (6) 2 (2) Decreased appetite 5 (5) 0 6 (5) 0 Ziftomenib was well tolerated, with a safety profile consistent with previous

studies,1,2 including: Low rates of ziftomenib-related myelosuppression No clinically significant QTc prolongation: 3 (3%)* patients: 1 Gr2, 2 Gr3 (all investigator-assessed) Differentiation syndrome: 15 (13%) Gr3; no Gr4-5 events 3%

discontinuations due ziftomenib-related AEs aNo patients had Grade 4-5 differentiation syndrome. *All 3 patients were on additional medications associated with QTc prolongation: 2 patients had electrolyte abnormalities and 1 patient had prior

diagnosis of atrial fibrillation.

CONCLUSIONS In the pivotal

KOMET-001 phase 2 study, the primary endpoint was met Ziftomenib achieved clinically meaningful, MRD-negative responses in this heavily pretreated R/R NPM1-m AML population Similar response rates were seen, regardless of prior therapies, including

HSCT and venetoclax Ziftomenib monotherapy was well tolerated with a safety profile consistent with previous studies Low rates of ziftomenib-related myelosuppression 3% ziftomenib-related discontinuations No clinically significant QTc prolongation

Differentiation syndrome was managed with protocol-specified mitigation strategies; no Grade 4-5 DS events NDA submitted for ziftomenib monotherapy as a new potential treatment option for adult patients with R/R NPM1-m AML Ziftomenib

combination studies are currently ongoing in both newly diagnosed and R/R AML (KOMET-007, KOMET-008)

ZIFTOMENIB GLOBAL DEVELOPMENT PLAN

Mollie Leoni, M.D. - Chief Medical Officer, Kura Oncology

KURA AND KYOWA KIRIN ARE

INVESTIGATING ZIFTOMENIB ACROSS THE AML CONTINUUM IN UP TO 50% OF PATIENTS for Whom Menin-KMT2A Pathway is a Disease Driver FRONTLINE IC or NIC Tx or tolerable therapy Transplant/ No Transplant Targeted Tx if FLT3m and/or NPM1m Non-Intensive